Sola Adeleke at COGC 2026: From New Drug Approval to Real
Clinical oncologist Sola Adeleke discussed the significant gap between the regulatory approval of cancer drugs and their actual accessibility in community hospitals. He highlighted how factors like local infrastructure, pricing, and workforce capacity create disparities in patient care.
Why it matters
This highlights systemic inequities in healthcare delivery, where geographic location and hospital type dictate the quality of life-saving treatments patients receive.
At the Community Oncology Global Congress ( COGC 2026 ), organized by OncoDaily, Sola Adeleke , clinical oncologist and Academic Clinical Fellow at King’s College London, focused on the gap between approving a new cancer treatment and making sure patients can actually access it.
His presentation, “Access Beyond Approval: Community Oncology in Western Europe – Advancing Quality, Innovation and Integrated Care,” looked at how reimbursement, local infrastructure, molecular testing, workforce capacity, and geography can shape what happens after a therapy receives regulatory approval.
A cancer drug can be approved in Europe and still take years to reach a patient in a district hospital. Adeleke’s talk focused on everything that happens in that gap – from pricing and reimbursement to staffing, molecular testing, local infrastructure, and the postcode privilege that can still shape who gets access to innovation.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in